Livedoid Vasculopathy with Hyperhomocysteinemia When Rivaroxaban Has Not Achieved Rapid Pain Relief

This protocol applies to patients with livedoid vasculopathy (LV) and concurrent hyperhomocysteinemia in whom the previous anticoagulation-based treatment line did not achieve its intended goal of rapid pain relief.

Clinical scenario Livedoid vasculopathy occurring in the context of hyperhomocysteinemia. This metabolic condition is a recognised factor in LV management and requires targeted co-treatment alongside standard LV care.

Previous treatment — failure condition The prior step — centred on rivaroxaban combined with vitamins B6, B12, and folic acid — did not achieve its primary goal of rapid pain relief. The present protocol is the structured next line taken after that failure.

Next-line approach (partial overview) For treatment-refractory LV, an intravenous immunoglobulin (IVIG)-based intervention is the approach considered at this stage. The complete administration details, criteria, and full regimen are contained within the structured protocol.

Treatment goal: Significant pain relief.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1111/ddg.14520

Patients with hyperhomocysteinemia should receive additional treatment with the vitamins B6, B12, and folic acid (off label).

IVIG treatment is recommended in treatment-refractory LV (off label).

The authors recommend a dose of 2 g/kg BW which may be split into several doses and administered over a period of 2–5 days (off label).

Monshi et al. reported significant pain relief and an increase in DLQI after only six treatment cycles.

View source ↗